Abstract
Dipyridamole was introduced on the market as coronary vasodilator drug more than half a century ago and is still used as antithrombotic and vasodilator. Among cellular targets, it inhibits phosphodiesterases and raises extracellular levels of adenosine through inhibition of adenosine reuptake by red blood cells. As a consequence, endocellular levels of cyclic nucleotides are upregulated. The rise of cGMP in vascular smooth mu scle cells and of cAMP in platelets provide the mechanism of vasodilation and antithrombosis, which are further potentiated by the release of PGI2 consequent on the increase in endothelial cell cAMP. These effects support the use of dipyridamole in cardiovascular diseases in which the drug is approved for the secondary prevention of cerebrovascular events. On the other hand, dipyridamole has been shown to possess a potent, little perceived, antioxidant activity of potential use in the several fields where pathophysiological pathways are dependent on oxidative stress, including those occurring in atherosclerosis, thrombosis, CNS-related diseases, and cancer.
Keywords: Antioxidant, Atherosclerosis, Cancer, Coronary artery disease, Dipyridamole, Ischemia-reperfusion injury, Neurodegeneration, Neuroprotection.
Current Topics in Medicinal Chemistry
Title:Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Volume: 15 Issue: 9
Author(s): Marco Ciacciarelli, Chiara Zerbinati, Francesco Violi and Luigi Iuliano
Affiliation:
Keywords: Antioxidant, Atherosclerosis, Cancer, Coronary artery disease, Dipyridamole, Ischemia-reperfusion injury, Neurodegeneration, Neuroprotection.
Abstract: Dipyridamole was introduced on the market as coronary vasodilator drug more than half a century ago and is still used as antithrombotic and vasodilator. Among cellular targets, it inhibits phosphodiesterases and raises extracellular levels of adenosine through inhibition of adenosine reuptake by red blood cells. As a consequence, endocellular levels of cyclic nucleotides are upregulated. The rise of cGMP in vascular smooth mu scle cells and of cAMP in platelets provide the mechanism of vasodilation and antithrombosis, which are further potentiated by the release of PGI2 consequent on the increase in endothelial cell cAMP. These effects support the use of dipyridamole in cardiovascular diseases in which the drug is approved for the secondary prevention of cerebrovascular events. On the other hand, dipyridamole has been shown to possess a potent, little perceived, antioxidant activity of potential use in the several fields where pathophysiological pathways are dependent on oxidative stress, including those occurring in atherosclerosis, thrombosis, CNS-related diseases, and cancer.
Export Options
About this article
Cite this article as:
Ciacciarelli Marco, Zerbinati Chiara, Violi Francesco and Iuliano Luigi, Dipyridamole: A Drug with Unrecognized Antioxidant Activity, Current Topics in Medicinal Chemistry 2015; 15 (9) . https://dx.doi.org/10.2174/1568026615666150220111942
DOI https://dx.doi.org/10.2174/1568026615666150220111942 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Challenges in Treatment of Inappropriate Sinus Tachycardia
Current Cardiology Reviews Highlighting Exosomes’ Function in Cardiovascular Diseases
Current Cardiology Reviews Regulative Roles of Ghrelin in Ingestive Behavior, Upper Gastrointestinal Motility, and Secretion
Current Nutrition & Food Science Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
Current Stem Cell Research & Therapy The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Peripartum Cardiomyopathy: An Intensivist's Perspective
Current Women`s Health Reviews Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
Current Medicinal Chemistry Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy